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disorder: a systematic review and meta-analysis
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Metabolic syndrome (MetS) and its components are highly predictive of cardiovascular diseases. The primary aim of this systematic review
and meta-analysis was to assess the prevalence of MetS and its components in people with schizophrenia and related psychotic disorders,
bipolar disorder and major depressive disorder, comparing subjects with different disorders and taking into account demographic variables
and psychotropic medication use. The secondary aim was to compare the MetS prevalence in persons with any of the selected disorders ver-
sus matched general population controls. The pooled MetS prevalence in people with severe mental illness was 32.6% (95% CI: 30.8%-
34.4%; N5198; n552,678). Relative risk meta-analyses established that there was no significant difference in MetS prevalence in studies
directly comparing schizophrenia versus bipolar disorder, and in those directly comparing bipolar disorder versus major depressive disorder.
Only two studies directly compared people with schizophrenia and major depressive disorder, precluding meta-analytic calculations. Older
age and a higher body mass index were significant moderators in the final demographic regression model (z523.6, p50.0003, r250.19).
People treated with all individual antipsychotic medications had a significantly (p<0.001) higher MetS risk compared to antipsychotic-na€ıve
participants. MetS risk was significantly higher with clozapine and olanzapine (except vs. clozapine) than other antipsychotics, and signifi-
cantly lower with aripiprazole than other antipsychotics (except vs. amisulpride). Compared with matched general population controls, peo-
ple with severe mental illness had a significantly increased risk for MetS (RR51.58; 95% CI: 1.35-1.86; p<0.001) and all its components,
except for hypertension (p50.07). These data suggest that the risk for MetS is similarly elevated in the diagnostic subgroups of severe mental
illness. Routine screening and multidisciplinary management of medical and behavioral conditions is needed in these patients. Risks of indi-
vidual antipsychotics should be considered when making treatment choices.
Key words: Metabolic syndrome, severe mental illness, schizophrenia, bipolar disorder, major depressive disorder, antipsychotics
(World Psychiatry 2015;14:339–347)
People with severe mental illness (SMI), including schizo-
phrenia and related psychotic disorders, bipolar disorder
and major depressive disorder (MDD), experience a two-
three times higher mortality rate than the general population
(1,2). This mortality gap translates into a 10-20 year short-
ened life expectancy (3,4) and appears to be widening (5).
About 60% of the excess mortality observed in SMI is due to
physical comorbidities, predominantly cardiovascular dis-
eases (CVD) (6). Factors predisposing people with SMI to
CVD include antipsychotic medication and unhealthy life-
styles (7) as well as their reduced likelihood to receive stan-
dard levels of medical care (8-12).
To assist clinicians in identifying and treating patients at
an increased risk of CVD, the concept of metabolic syn-
drome (MetS) has been introduced. MetS is defined by a
combination of central obesity, high blood pressure, low
high-density lipoprotein (HDL) cholesterol, elevated trigly-
cerides and hyperglycaemia. In the general population, these
clustered risk factors have been associated with the develop-
ment of CVD and excess mortality (13-15). Current defini-
tions (16-19) for MetS are aimed at being easy to use in
clinical settings and share similar diagnostic thresholds (20).
However, the role of abdominal obesity is central to the
MetS definition of the International Diabetes Federation
(IDF) (18), with provision of ethnic specific thresholds for
waist circumference, while central obesity is not a mandato-
ry criterion in the MetS definition of the National Cholester-
ol Education Program (NCEP) Adult Treatment Panel III
(ATP III) (16,17). As a prevalent condition and predictor of
CVD across racial, gender and age groups, MetS provides
the opportunity to identify high-risk populations and prevent
the progression of some major causes of morbidity and mor-
tality (20).
Previous meta-analyses (21-24) documented that people
with SMI have an increased risk for developing MetS com-
pared with the general population. A brief meta-analytic
report comparing MetS frequencies in patients with schizo-
phrenia and bipolar disorder found that these populations
are at similar risk (25). However, these findings should be
interpreted with caution, since comparisons were performed
at study level and not limited to studies directly comparing
the two populations, and patient samples were not matched
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for age and illness duration (26). Meta-analytic comparisons
of schizophrenia and related psychotic disorders or bipolar
disorder with major depressive disorder are currently lack-
ing. In the same way, meta-analytic data including all major
diagnostic SMI subgroups (i.e., schizophrenia and related
psychotic disorders versus bipolar disorder versus major
depressive disorder) are absent in the literature.
Large-scale pooled analyses in the SMI population are
highly relevant, as they enable investigation of risk factors
across large numbers of studies and participants, dissecting
risk factors for MetS associated with SMI from those inde-
pendent of it. Pooling data across major diagnostic categories
allows for investigation of the effect of demographic variables
(age, illness duration, gender, setting, geographical region)
and treatments (particularly mood stabilizers and antipsy-
chotics, as well as polypharmacotherapy versus monother-
apy). If risk stratification is observed, this could potentially
help guide clinicians in monitoring and treatment.
We conducted a systematic review and meta-analysis to
assess pooled prevalences of MetS and its components in
people with schizophrenia and related psychotic disorders,
bipolar disorder and major depressive disorder, selecting
studies directly comparing subjects with different disorders
and taking into account demographic variables and medica-
tion use. Our secondary aim was to compare the MetS prev-
alence in persons with any of the selected disorders versus
matched general population controls.
METHODS
Inclusion and exclusion criteria
This systematic review was conducted in accordance
with the Meta-analysis Of Observational Studies in Epide-
miology (MOOSE) guidelines (27) and in line with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) standard (28). We included observa-
tional studies (cross-sectional, retrospective and prospective
studies) in adults that fulfilled the following criteria: a) a
diagnosis of schizophrenia or a related psychotic disorder,
bipolar disorder or major depressive disorder according to
the DSM-IV or ICD-10, irrespective of clinical setting (inpa-
tient, outpatient or mixed); and b) a MetS diagnosis accord-
ing to non-modified ATP-III (16), ATP-III-A (17), IDF (18)
or World Health Organization (19) standards. For a ran-
domized control trial, we extracted the variables of interest
at baseline. There were no language or time restrictions.
For estimation of the prevalence of MetS, we excluded
studies with: a) non-standardized diagnoses, b) non-
standardized definitions of MetS, c) insufficient data for
extraction of MetS frequencies, d) restriction to patients at
risk for or without cardiovascular diseases, and e) restriction
to children and/or adolescents. In the case of multiple publi-
cations from the same study, only the most recent paper or
the article with the largest sample was included. When
required, we contacted the primary/corresponding authors
of potential studies to confirm eligibility, or to acquire the
variables of interest if they were not available in the publi-
cation.
Search criteria, study selection and critical appraisal
Two independent authors (DV, BS) searched MEDLINE,
PsycARTICLES, EMBASE and CINAHL from database
inception to January 1, 2015. Key words used were “metabolic
syndrome” AND “severe mental illness” OR “schizophrenia”
OR “bipolar disorder” OR “depression” OR “depressive dis-
order” in the title, abstract or index term fields. Manual
searches were also conducted using the reference lists from
recovered articles and recent meta-analyses (21-24).
After the removal of duplicates, the reviewers screened
the titles and abstracts of all potentially eligible articles. Both
authors applied the eligibility criteria, and a list of full text
articles was developed through consensus. The reviewers
then considered the full texts of these articles and the final
list of included articles was reached through consensus. A
third reviewer (AJM) was available for mediation throughout
this process.
Methodological appraisal was performed according to
PRISMA standards (28), including evaluation of bias (con-
founding, overlapping data, publication bias). Publication
bias was tested using the Egger’s regression method (29) and
Begg-Mazumdar test (30), with a p value <0.05 suggesting
the presence of bias.
Statistical analyses
We pooled individual study data using the DerSimonian-
Laird proportion method with StatsDirect (31). The trim-
and-fill approach (32) was used to adjust the overall estimate
for funnel plot asymmetry. Due to anticipated heterogeneity,
a random effects meta-analysis was employed. Heterogeneity
was measured with the Q statistic, yielding a chi-square p val-
ue, with p<0.05 indicating significant heterogeneity of the
pooled results. We calculated the relative risk (RR) to investi-
gate the prevalence of MetS and its components within and
across SMI subgroups, the latter only in those studies directly
comparing diagnostic subgroups. Moreover, we compared
the prevalence of MetS between people with schizophrenia,
bipolar disorder and major depressive disorder versus general
population control groups that were matched on age and sex,
also only using data from studies in which they were directly
compared. In both analyses, only comparisons of specific
SMI groups or an SMI group with a matched general popula-
tion group were included that had been performed within the
same study, in order to minimize variability of MetS frequen-
cies due to different sampling and assessment procedures.
In order to increase homogeneity of compared samples
and eliminate smaller studies with less precise point estimates,
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we also conducted sensitivity analyses, restricting the sam-
ple to large, population-based studies. Furthermore, in the
entire dataset, we conducted subgroup analyses (including
v2 tests, t tests, odds ratios) to investigate differences be-
tween the three main diagnostic subgroups and between
first episode and multi-episode illness, gender differences,
and differences across medication regimes (antipsychotics,
antidepressants, mood stabilizers, monotherapy versus poly-
pharmacotherapy) and geographical regions. In order to
reduce heterogeneity, we did not calculate diagnostic and
gender differences across studies, but pooled only data
of studies that compared these differences on a patient
level.
Further, we conducted meta-regression analyses to inves-
tigate potential moderators (age, percentage of males, illness
duration, body mass index, smoking rates) with Comprehen-
sive Meta Analysis (version 3). Finally, since patients with a
first episode of schizophrenia and those with chronic schizo-
phrenia differ significantly in age, and since older age is a sig-
nificant moderator of higher MetS rates, we also conducted a
multivariable meta-regression analysis, adding both first ver-
sus multi-episode schizophrenia and age as variables into the
analysis.
RESULTS
Search results and included participants
Our search yielded 429 publications, of which 198 met
inclusion criteria (Figure 1). The list of included and exclud-
ed studies (with reasons) is available upon request. The final
sample comprised 52,678 unique persons with SMI. Sample
sizes ranged from 14 to 3,568 participants, with a mean sam-
ple size of 264. Mean age was 41.3 years (range 22.2-73.2),
and mean illness duration was 12.4 years. Fifty-seven stud-
ies (n5 12,560) reported smoking frequencies, and half of
the included participants (50.4%, 95% CI: 46.7%-54.0%,
Q5 1192.0, p<0.001) smoked. The mean body mass index
of the sample was 27.3 (SD5 2.7).
Records screened after duplicates and 
irrelevant papers were removed 
(N=429) 
Records excluded on title/abstract level 
(N=55) 
Reasons: review (N=47), no full text 
obtained (N=8) 
Full-text articles assessed for 
eligibility (N=374)
Records identified through database 
searching (N=8,852) 
CINAHL: N=282 
EMBASE: N=1,332 
MEDLINE: N=1,620 
PsycARTICLES: N=5,618
Additional records identified through other 
sources (N=12)
Articles excluded (N=176) 
Reasons: overlap with included papers 
(N=80), not on MetS prevalence 
(N=33), not on severe mental illness 
(N=29), modified MetS criteria (N=9), 
no MetS prevalence obtained (N=8), 
CVD risk factors inclusion criterion 
(N=7), CVD risk factors exclusion 
criterion (N=3), only incidence rates 
(N=2), psychiatric diagnoses not clear 
(N=2), limited to children and 
adolescents (N=2), MetS criteria 
unclear (N=1) Full-text articles included in the 
meta-analysis (N=198)
Figure 1 Flow diagram for the search strategy. MetS – metabolic syndrome, CVD – cardiovascular disease
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Prevalence of metabolic syndrome and its components
The estimated weighted mean prevalence of MetS was
32.6% (95% CI: 30.8%-34.4%, Q5 3696, p<0.001, n5
52,678). The Begg-Mazumdar (Kendall’s tau b5 0.15, p5
0.0015) and Egger test (bias5 1.46, 95% CI: 0.15-2.77,
p50.0292) indicated some publication bias. The trim-and-
fill method demonstrated that adjusting for publication bias
had little effect on the pooled MetS estimate, which was vir-
tually identical (32.5%, 95% CI: 30.8%-34.2%, Q5 2991,
p<0.01, n5 52,678). Restricting the analysis to population-
based studies (N5 29, n5 18,594), the overall weighted
mean prevalence of MetS was 35.9% (95% CI: 31.8%-
40.0%, Q5 934.8, p<0.001).
Sixty-five studies reported on obesity frequency defined
as waist circumference >102 cm in males and >88 cm in
females (ATP-III or ATP-III-A), while 14 studies reported
the obesity frequency following the ethnicity-specific IDF
criteria. Overall, the proportion of patients with abdominal
obesity was 50.3% by the ATP definitions (n5 20,210; 95%
CI: 46.9%-53.7%, Q5 1.6, p<0.001) and 63.2% according
to IDF (n5 3,789; 95% CI: 53.6%-72.3%, Q5480.9, p<
0.001). In studies reporting on hyperglycaemia, the frequen-
cy was 18.8% (N5 56, n5 17,508; 95% CI: 16.6%-21.2%,
Q5 906.9, p<0.001) when the threshold was 110 mg/dl
(ATP-III), while it was 23.0% (N5 28, n58,205; 95% CI:
17.3%-29.2%, Q5 1.1, p<0.001) when the threshold was
100 mg/dl (ATP-III-A and IDF). Hypertriglyceridemia was
present in 36.2% (N5 87, n5 26,577; 95% CI: 33.1%-
39.3%, Q5 2.7, p<0.001). Low HDL cholesterol was pre-
sent in 39.1% (N5 86, n5 26,193; 95% CI: 36.4%-41.9%,
Q5 1.9, p<0.001). Hypertension (ATP-III, ATP-III-A and
IDF) was present in 39.3% (N588, n5 27,441; 95% CI:
36.1%-42.5%, Q52.7, p<0.001).
Subgroup analyses and predictors of metabolic syndrome
Diagnostic subgroups
The pooled MetS prevalence was 33.4% (95% CI: 30.8%-
36.0%, Q51955.0, p<0.001) in people with schizophrenia
(N593, n5 29,596), and 34.6% (95% CI: 29.3%-40.0%,
Q5110.2, p<0.001) in those with related psychotic disor-
ders (N5 13, n52,850). Similar pooled MetS prevalences
were observed in patients with bipolar disorder (31.7%, 95%
CI: 27.3%-36.3%, Q5 843.5, p<0.001; N5 33, n5 5,827)
and major depressive disorder (31.3%, 95% CI: 27.3%-
35.5%, Q5 142.7, p<0.001; N5 19, n55,415). In
population-based studies, the pooled prevalence of MetS
was 38.9% (95% CI: 34.6%-43.4%, Q5 458.1, p<0.001; N5
20, n5 12,770) for schizophrenia and 22.7% (95% CI:
20.4%-25.1%, Q5 2.28, p5 0.31; N5 3, n51,503) for
major depressive disorder. There were insufficient data for
bipolar disorder.
The releative risk of MetS versus age- and gender-matched
healthy controls was 1.87 in schizophrenia and related psy-
chotic disorders (95% CI: 1.53-2.29; p<0.001, Q518.3,
p5 0.03; N5 11, n51,413), 1.58 in bipolar disorder (95%
CI: 1.24-2.03; p<0.001, Q56.6, p5 0.25; N5 6, n51,125)
and 1.57 in major depressive disorder (95% CI: 1.38-1.79,
p<0.001, Q5 19.0, p50.26; N5 17, n5 5,267).
Relative risk meta-analyses established that there was no
significant difference in MetS in studies directly comparing
schizophrenia (39.2%, 95% CI: 30.5%-48.3%; n5 2,338) ver-
sus bipolar disorder (35.5%, 95% CI: 27.0-44.3%; n5 2,077)
(N5 10, RR5 0.92, 95% CI: 0.79%-1.06%; v251.33, p5
0.24; Q521.3, p<0.011). Similarly, there were no differ-
ences in the study directly comparing bipolar disorder
(29.2%, 95% CI: 14.5%-46.2%; n5 137) versus major depres-
sive disorder (34.0%, 95% CI: 19.4%-50.3%; n5176)
(N5 4; RR5 0.87, 95% CI: 0.48- 1.55; v25 0.21, p5 0.64;
Q5 7.73, p5 0.0518). Only two studies directly compared
MetS in people with schizophrenia and major depressive dis-
order, precluding meta-analytic calculations.
Comparing MetS in first versus multi-episode patients
within illness subgroups, first episode psychosis patients
(13.7%, 95% CI: 10.4%-16.9%, Q5 8.659, p5 0.034; N5 4,
n5 424) had a significantly lower MetS risk than those with
multi-episode schizophrenia (34.2%, 95% CI: 30.8%-36.0%,
Q5 1,955, p<0.001; N5 105, n5 29,596) (z528.9, p<
0.001). In order to assess if the difference in MetS rates
remained significant when age was entered into the analyses,
we conducted a multivariable meta-regression analysis. With-
in this, we pooled the prevalence of MetS in first and multi-
episode schizophrenia and found that, although mean age
predicted MetS prevalence (coefficient5 0.0296; 95% CI:
0.013 to 0.0463, z5 3.49, p5 0.005), first episode was also a
unique predictor of lower MetS (coefficient520.7517; 95%
CI: 21.4877 to 20.0157; z522, p5 0.04; r25 0.24). There
were no data in first-episode bipolar disorder or major
depressive disorder patients, precluding a comparison with
multi-episode patients.
Demographic variables
A relative risk meta-analysis across 64 studies directly
comparing MetS frequencies in male (33.5%, 95% CI:
30.0%-36.7%, Q5 814, p<0.001; n5 10,798) versus female
(33.4%, 95% CI: 31.5%-38.4%, Q5 615, p<0.001; n5
8,027) participants with SMI found no gender differences
(RR5 0.94; 95% CI: 0.85-1.02; v25 2.06, p5 0.15; Q5
232.0, p<0.011).
Separate meta-regression analyses revealed that higher
MetS frequencies were moderated by older age (coeffi-
cient5 0.0278; 95% CI: 0.0178-0.0379, z5 5.5, p<0.0001),
longer illness duration (coefficient5 0.0339; 95% CI: 0.0115-
0.0564, z5 2.96, p5 0.003) and higher body mass index
(coefficient5 0.1537; 95% CI: 0.095-0.2123, z55.14, p<
0.0001), but not by smoking status (p5 0.49). When all
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significant predictors were entered in one meta-regression
model, body mass index (coefficient50.142, 95% CI: 0.0438-
0.2405, z5 2.83, p50.004) and age (coefficient5 0.0556,
95% CI: 0.0025-0.1087, z5 2.05, p50.04) remained signifi-
cant predictors, whilst illness duration did not (p5 0.19).
Overall, the final model was a significant predictor of the
variance in MetS (z523.6, p50.0003; r25 0.19).
Pooled MetS prevalences per geographical region and
country (if N5) can be found in Table 1. The MetS preva-
lence was significantly higher in Australia and New Zealand
compared with all other regions (p<0.001). Pooled MetS
prevalences per country ranged from 25.4% (95% CI:
18.5%-32.9%) in Brazil to 50.2% (95% CI: 32.9%-67.4%) in
Australia.
Medication use
Data from five studies demonstrated a trend for lower
pooled MetS prevalence in participants receiving mono-
therapy (30.4%, 95% CI 25.4%-35.5%, Q5 15.2, p5 0.004;
n51,364) versus polytherapy (35.2%, 95% CI: 23.8%-
47.5%, Q518.8, p5 0.008; n5 313) (RR5 0.81; 95% CI:
0.66-1.01; v253.41, p50.065; Q55.87, p5 0.21).
Forty-eight papers including 147 analyses reported on
antipsychotics (monotherapy and N5). The prevalence of
MetS was lowest in antipsychotic-na€ıve participants (10.2%,
95% CI: 6.8%-14.3%). Among those receiving antipsychotics,
participants taking aripiprazole had the lowest MetS preva-
lence (19.4%, 95% CI:8.0%-34.2%; N5 6), whilst those tak-
ing clozapine had the highest (47.2%, 95% CI: 42.0%-52.6%;
N5 30). Patients treated with amisulpride, typical antipsy-
chotics, risperidone, olanzapine and quetiapine had MetS
frequencies of 22.8% (95% CI: 7.6%-43.2%; N5 5), 28.0%
(95% CI: 19.8%-37.2%; N5 15), 30.7% (95% CI: 23.7%-
38.1%; N5 20), 36.2% (95% CI: 31.8%-40.9%; N5 26) and
37.3% (95% CI: 27.4-47.8%; N5 11), respectively.
An overview of the odds ratios comparing individual
medications (if monotherapy and N5) with each other (at
study level) is presented in Table 2. Patients treated with all
individual antipsychotic medications had significantly
(p<0.001) higher MetS risk compared to antipsychotic-
na€ıve participants. Those treated with clozapine consistent-
ly had significantly (p<0.001) higher MetS prevalence than
those treated with any other individual antipsychotic medi-
cation. Those treated with olanzapine had significantly
higher MetS prevalence than those treated with amisulpride
(p<0.05), aripiprazole (p<0.001), risperidone (p<0.01) and
typical antipsychotic medications (p<0.05). Those treated
with aripiprazole had significantly lower odds of MetS com-
pared to other antipsychotic medications (except vs. ami-
sulpride). There were insufficient data to compare the MetS
prevalence between antipsychotic-na€ıve persons and those
treated with specific antidepressants or mood stabilizers in
similar populations.
Table 1 Geographical differences in pooled metabolic syndrome (MetS) prevalence
Region No. studies Pooled MetS prevalence Cochran Q
Australia and New Zealand* 6 50.2% (95% CI: 35.3%-65.0%) 73.8, p<0.001
Middle-East 6 35.3% (95% CI: 31.3%-39.5%) 1287.6, p<0.001
North-America 46 32.4% (95% CI: 24.7%-40.8%) 38.0, p<0.001
Europe 81 32.0% (95% CI: 29.4%-34.7%) 1226.4, p<0.001
Asia 50 31.0% (95% CI: 27.7%-34.4%) 691.3, p<0.001
South-America 10 25.8% (95% CI: 20.7%-31.3%) 42.3, p<0.001
Country No. studies Pooled MetS prevalence Cochran Q
Australia 5 50.2% (95% CI: 32.9%-67.4%) 72.7, p<0.001
South Korea 7 38.9% (95% CI: 30.8%-47.3%) 103.3, p<0.001
The Netherlands 11 36.5% (95% CI: 29.0%-44.4%) 167.3, p<0.001
USA 38 36.4% (95% CI: 32.0%-40.9%) 1217.8, p<0.001
Croatia 7 33.1% (95% CI: 24.6%-42.3%) 39.1, p<0.001
Spain 12 31.0% (95% CI: 24.5%-37.9%) 210.3, p<0.001
Finland 5 30.4% (95% CI: 21.8%-39.8%) 17.9, p<0.001
Taiwan 13 29.8% (95% CI: 24.7%-35.1%) 124.1, p<0.001
Germany 6 28.7% (95% CI: 19.2%-39.2%) 62.8, p<0.001
Canada 5 27.4% (95% CI: 17.3%-38.7%) 44.2, p<0.001
India 16 26.3% (95% CI: 19.0%-34.3%) 193.0, p<0.001
Brazil 8 25.4% (95% CI: 18.5%-32.9%) 39.4, p<0.001
*Significantly higher than in other regions, p<0.01
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Risk of metabolic syndrome and its components in
persons with various disorders compared with general
population controls
Thirty studies also provided data on MetS prevalence in
healthy control subjects. In a pooled relative risk meta-
analysis, persons with SMIs (n56,610; 29.2%, 95% CI:
25.9%-32.6%; Q5 230, p<0.001), compared with general
population controls (n5 101,223; 18.1%, 95% CI: 15.8%-
20.5%, Q5230, p<0.001), had significantly increased risk of
MetS (RR5 1.58, 95% CI: 1.35-1.86, p<0.001; Q5 62,
p50.003).
People with severe mental illness had significantly in-
creased risk for abdominal obesity (N5 18; RR5 1.43,
95% CI: 1.23-1.66, p<0.001; Q5 198.8, p<0.001), low
HDL cholesterol (N5 19; RR5 1.33, 95% CI: 1.15-1.54,
p<0.001; Q5 114.7, p<0.001), hypertriglyceridemia (N5
19; RR5 1.49, 95% CI: 1.28-1.73, p<0.001; Q591.2, p<
0.001), and hyperglycaemia (N5 20; RR5 1.51, 95% CI:
1.24-1.84, p<0.001; Q5 94.4, p<0.001), with a statistical
trend for hypertension (N5 12; RR5 1.12, 95% CI: 0.99-
1.28, p5 0.07; Q5 127.1, p<0.001).
DISCUSSION
To our knowledge, this is the first meta-analysis of MetS
and its components including and comparing data from the
main SMIs: schizophrenia and related psychotic disorders,
bipolar disorder and major depressive disorder. Approxi-
mately one third, 32.6% (95% CI: 30.8%-34.4%), of this
population had MetS and the relative risk was 1.58 times
higher than in the respective general population. MetS prev-
alences were consistently elevated for each of the three diag-
nostic subgroups compared to the general population, and
comparative meta-analyses found no significant differences
across schizophrenia, bipolar disorder and major depressive
disorder. Importantly, we also showed for the first time on a
large meta-analytic scale that MetS risk differs significantly
across commonly used antipsychotic medications.
Knowledge of factors associated with the highest MetS
risk can help identify individuals at greatest need for intensive
monitoring and intervention. Consistent with population
studies (33,34), we found no significant difference between
men and women. Our results confirm earlier meta-analyses
(22,35) in that MetS prevalence was higher in individuals
with multi-episode schizophrenia compared with persons in
their first episode. The current meta-analysis adds to the liter-
ature that a first episode diagnosis is even a unique predictor
of lower MetS prevalence independent of mean age.
Also in line with data in the general population (36) and
earlier work in people with schizophrenia (23), increasing
age was a key predictor of MetS. When age and illness dura-
tion were entered into the same model, age was a more
important determinant of MetS. However, this may also be
due to the limited data available for illness duration com-
pared to age data. Since age is a relevant risk factor for
MetS in the general population too, the relative MetS risk
Table 2 Odds ratios for metabolic syndrome risk for individual antipsychotic medications (if monotherapy and N5)
Medication
Antipsychotic-
na€ıve Amisulpride Aripiprazole Clozapine Olanzapine Quetiapine Risperidone
Amisulpride 3.86*** (")
(2.54-5.84)
N515; n5999
/ / / / / /
Aripiprazole 3.25*** (")
(2.36-4.49)
N516; n51,319
0.84 ($)
(0.57-1.25)
N511; n5692
/ / / / /
Clozapine 7.81*** (")
(6.02-10.22)
N522; n52,398
2.02*** (")
(1.45-2.83)
N517; n51,177
2.40*** (")
(1.91-3.03)
N518; n52,091
/ / / /
Olanzapine 5.87*** (")
(4.53-7.67)
N522; n52,633
1.52* (")
(1.08-2.16)
N515; n52,006
1.81*** (")
(1.44-2.27)
N516; n52,326
0.75*** (#)
(0.65-0.86)
N522; n53,405
/ / /
Quetiapine 5.14*** (")
(3.75-7.07)
N521; n51,266
1.33 ($)
(0.90-1.97)
N516; n5639
1.58*** (")
(1.19-2.11)
N517; n5959
0.66*** (#)
(0.53-0.82)
N523; n52,038
0.88 ($)
(0.70-1.09)
N522; n52,273
/ /
Risperidone 4.57*** (")
(3.48-6.03)
N530; n52,025
1.18 ($)
(0.83-1.69)
N5 25; n5 1398
1.40*** (")
(1.10-1.79)
N526; n51,718
0.58*** (#)
(0.50-0.68)
N532; n52,797
0.78** (#)
(0.66-0.91)
N530; n53,032
0.89 ($)
(0.70-1.12)
N531; n51,665
/
Typical
antipsychotics
4.97*** (")
(3.83-6.51)
N517; n52,525
1.28 ($)
(0.91-1.83)
N512; n51,898
1.53*** (")
(1.23-1.91)
N5 13; n =2,218
0.64*** (#)
(0.55-0.73)
N519; n53,297
0.85* (#)
(0.74-0.97)
N517; n53,532
0.97 ($)
(0.77-1.21)
N518; n52,165
1.09 ($)
(0.93-1.28)
N527; n52,924
*Two-sided p<0.05, two-sided p<0.01, ***two-sided p<0.001
"5higher risk, #5 lower risk, $5no significant risk difference
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compared to the general population is greatest in younger
people with SMI and those treated with antipsychotics
(37,38). Considering the current meta-analytic data, it ap-
pears that a cumulative long-term effect of poor health
behaviors and psychotropic medication use places people
with SMI at the greatest risk for cardiometabolic disorders,
more so than psychiatric diagnosis per se.
Our data suggest that patients receiving all individual
antipsychotic medications are at higher MetS risk when
compared to those who are antipsychotic-na€ıve. In line
with the available literature (11,32,39-41), MetS risk was
significantly higher with clozapine, followed by olanzapine.
Moreover, MetS risk was significantly lower with aripipra-
zole than with each other antipsychotic for which data were
available, including pooled typical antipsychotics, with the
only exception of amisulpride. The lowest MetS prevalence
for aripiprazole is noteworthy, as antipsychotics with lower
cardiometabolic risk profiles in short-term studies are often
prescribed for higher risk patients in clinical care, which
may lead to a not reduced or even increased cardiometa-
bolic risk in naturalistic settings (42).
Our meta-analysis also highlighted geographical differ-
ences in MetS, which indicates the possible influence of life-
style and other environmental factors with or without genetic
risk differences. This finding may, however, be somewhat
affected by different MetS criteria, with IDF criteria, which
are often used in Australian studies, being associated with the
highest MetS prevalences. Nevertheless, people with SMI are
more likely than the general population to have unhealthy
lifestyle behaviors, such as being sedentary (43), smoking
(44) and having diets that are high in saturated fats and
refined sugars, while low in fruit and vegetables (45), placing
them at higher risk for MetS and CVD than the general popu-
lation. Thus, screening for and trying to minimize risk factors
(including adverse lifestyle factors and antipsychotic medica-
tion choice and use) should be a key priority in the multidisci-
plinary treatment of people with SMI (46-49).
Whilst this is the most comprehensive and thorough
meta-analysis of MetS in people with SMI conducted to
date, we acknowledge some limitations that are largely relat-
ed to the primary data. First, there was considerable method-
ological heterogeneity across studies. Second, because our
study findings were based on cross-sectional rather than lon-
gitudinal data, directionality of the association between
medication use and observed metabolic parameters cannot
be deduced with certainty; that is, it is possible that those
with inherently higher metabolic risk factors may be more
likely to receive antipsychotics. Third, variables such as clini-
cal subtypes of major depressive and bipolar disorder and
concomitant or previous use of antidepressants and mood
stabilizers were not reported or were insufficiently reported
or controlled for in most available studies. Fourth, a threat to
the validity of any meta-analysis is publication bias and het-
erogeneity, which we encountered in several of our analyses.
However, although the main findings were heterogeneous,
they were also highly robust and not influenced by publica-
tion bias, being virtually unaltered after applying the trim-
and-fill method. Fifth, there were inadequate data on ethnic
distribution and lifestyle behaviors, precluding meta-analytic
assessment of these factors as moderating or mediating varia-
bles. Despite the above-mentioned caveats, this is the largest
study of MetS risk and its moderators in people with SMI,
and the first meta-analysis pooling and comparing all avail-
able data across patients with schizophrenia, bipolar disorder
and major depressive disorder, comparing MetS risk across
different antipsychotics and comparing the pooled risk of the
three main SMI categories as well as the individual diagnostic
groups with concurrently assessed, matched general popula-
tion control groups.
Since antipsychotic medications are increasingly used as
frontline treatments for bipolar disorder (50) and major
depressive disorder (51), research on the underlying mecha-
nisms for the development of metabolic abnormalities after
pharmacotherapy initiation is urgently needed. Future stud-
ies should also examine whether different clinical subtypes
of depression (i.e., melancholic or atypical) and bipolar dis-
order (e.g., type 1 or 2, mixed, cyclothymic), different mood
states (manic, depressive or euthymic), or different antide-
pressant or mood stabilizers significantly modulate MetS
risk. For example, previous studies (52) found that some
antidepressants may, in some circumstances, reduce hyper-
glycaemia, normalize glucose homeostasis and also increase
insulin sensitivity, whereas others, including tricyclic anti-
depressants, may exacerbate glycaemic dysfunction or have
little effect on glucose homeostasis (53,54). Further, persons
with atypical depression have significantly higher levels of
inflammatory markers, body mass index, waist circumfer-
ence and triglycerides, and lower HDL cholesterol than
those with melancholic depression (55).
The pathophysiology underlying the association between
SMI and MetS is complex and not well understood, requir-
ing further investigation. Emerging evidence (56-59) sug-
gests that they share pathophysiological features, including
hypothalamic-pituitary-adrenal and mitochondrial dysfunc-
tion, neuro-inflammation, common genetic links and epige-
netic interactions. Future research should comprehensively
assess MetS risk factors and evaluate the optimal monitor-
ing regimen and interventions. Moreover, long-term follow-
up is required to accurately document the emergence of
more distal outcomes, such as diabetes, ischemic heart dis-
ease, medical costs, and premature mortality (58).
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